Clinical trials: Prostate Cancer Stage
Prostate Cancer
A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer
This study will look at the effect of adding the drug Palbociclib to CAD (Combined Androgen Deprivation) therapy in patients with RB (Retinoblastoma Protein) positive hormone sensitive prostate cancer.
- Trial name
- NCT02059213
- Testing
- Ibrance, Bicalutamide, Zoladex
- Where
- 8 sites in United States
- Volunteers
- 72 people
- Sponsor
- University of Michigan Rogel Cancer Center
Prostate Neoplasms
A Study to Determine the Maximum Tolerated Dose of ASG-5ME in Subjects With Castration-Resistant Prostate Cancer
The purpose of this dose escalation study is to determine the Maximum Tolerated Dose (MTD) and the recommended Phase 2 dose of ASG-5ME in subjects with castration-resistant prostate cancer (CRPC).
- Trial name
- NCT01228760
- Testing
- ASG-5ME
- Where
- 4 sites in United States
- Volunteers
- 46 people
- Sponsor
- Astellas Pharma Inc
Prostate Cancer, Male Erectile Disorder
ED Recovery in Men Age </=65 Treated With Bilateral Nerve Sparing Robotic Assisted Prostatectomy for Prostate Cancer
RATIONALE: Sildenafil citrate and alprostadil may help patients who have undergone prostatectomy for prostate cancer to recover from erectile dysfunction.
- Conditions
- Prostate Cancer, Male Erectile Disorder, Stage I Prostate Cancer, Stage II Prostate Cancer
- Trial name
- NCT00544076
- Testing
- sildenafil citrate, alprostadil, robotic-assisted laparoscopic surgery
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- City of Hope Medical Center
Prostatic Neoplasms
Standard Dose Versus High Dose and Versus Extended Standard Dose Radium-223 Dichloride in Castration-resistant Prostate Cancer Metastatic to the Bone
This study will assess different doses and regimens of radium-223 dichloride on the incidence of symptomatic skeletal events. Eligible subjects must have castration resistant prostate cancer with 2 or more skeletal metastases…
- Trial name
- NCT02023697
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223)
- Where
- 68 sites in United States, Australia and 13 more
- Volunteers
- 391 people
- Sponsor
- Bayer
Metastatic Castration-resistant Prostate Cancer
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer
The purpose of this study is to evaluate the efficacy and safety (including evaluating side effects) of combination of olaparib and abiraterone versus placebo and abiraterone in patients with metastatic castration-resistant…
- Trial name
- NCT03732820
- Testing
- olaparib, abiraterone acetate
- Where
- 132 sites in United States, Australia and 15 more
- Volunteers
- 895 people
- Sponsor
- AstraZeneca
Metastatic Castration-resistant Prostate Cancer
A Study of TmPSMA-02 Chimeric Antigen Receptor (CAR) T-cells in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
An open-label, multi-center, Phase 1/2 study to determine the safety, tolerability, and feasibility of dosing adult patients with mCRPC with genetically modified autologous T-cells (TmPSMA-02) engineered to express a CAR capable…
- Trial name
- NCT05489991
- Testing
- TmPSMA-02
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Tceleron Therapeutics, Inc.
Prostate Cancer
A Phase II Trial of TPI 287 in Patients With Metastatic Prostate Cancer
The primary objective of the study is to determine the response rate to TPI 287 in patients with metastatic, hormone-refractory prostate cancer who have had one prior taxane regimen.
- Trial name
- NCT00479635
- Testing
- TPI 287
- Where
- 6 sites in United States
- Volunteers
- 26 people
- Sponsor
- Cortice Biosciences, Inc.
Prostate Cancer
Hypofractionated Stereotactic Body Radiation Therapy as a Boost to the Prostate
In this study, participants will have standard Androgen Deprivation Therapy and undergo standard external beam radiation therapy to the prostate and at-risk lymph nodes by Intensity Modulated Radiation Therapy.
- Trial name
- NCT01508390
- Testing
- CyberKnife Boost
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Boston Medical Center
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
This phase Ib trial determines if samples from a patient's cancer can be tested to find combinations of drugs that provide clinical benefit for the kind of cancer the patient has.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia, Ann Arbor Stage III Hodgkin Lymphoma
- Trial name
- NCT03878524
- Testing
- Abemaciclib, Abiraterone, Afatinib
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- OHSU Knight Cancer Institute
Prostate Cancer
S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Androgens can stimulate the growth of prostate cancer cells.
- Trial name
- NCT00028769
- Testing
- bicalutamide, estramustine, etoposide
- Where
- 91 sites in United States
- Volunteers
- 41 people
- Sponsor
- SWOG Cancer Research Network
Metastatic Castrate-Resistant Prostate Cancer (mCRPC),, Efficacy,
Investigating Safety, Tolerability and Efficacy of AZD5363 in Prostate Cancer.
To investigate the safety, tolerability and anti-tumour activity of AZD5363, as monotherapy, in patients with metastatic Castrate-Resistant Prostate Cancer.
- Conditions
- Metastatic Castrate-Resistant Prostate Cancer (mCRPC),, Efficacy,, Safety and Tolerability,, Pharmacokinetics,
- Trial name
- PYRUS (NCT01692262)
- Testing
- Intermittent dosing of AZD5363
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 59 people
- Sponsor
- AstraZeneca
Prostate Cancer Stage I AJCC V6, Prostate Cancer Stage II
High-Intensity Focused Ultrasound in Treating Participants With Intermediate and High-risk Prostate Cancer
This phase II trial studies how well high-intensity focused ultrasound works in treating participants with intermediate and high-risk prostate cancer.
- Conditions
- Prostate Cancer Stage I AJCC V6, Prostate Cancer Stage II, Prostate Cancer Stage III
- Trial name
- NCT03514927
- Testing
- Contrast-Enhanced Ultrasound, High-Intensity Focused Ultrasound, Laboratory Biomarker Analysis
- Where
- United States
- Sponsor
- University of Southern California
Prostate Cancer, Castration Resistant Prostate Cancer
Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100
This study will evaluate the effect of cabozantinib compared to prednisone on overall survival in men with previously treated metastatic castration-resistant prostate cancer with bone-dominant disease who have experienced disease…
- Conditions
- Prostate Cancer, Castration Resistant Prostate Cancer, Pain, Prostatic Neoplasms
- Trial name
- COMET-1 (NCT01605227)
- Testing
- cabozantinib, prednisone
- Where
- 264 sites in United States, Australia and 12 more
- Volunteers
- 1,028 people
- Sponsor
- Exelixis
Prostate Cancer
Low, Intermediate, or High Dose Suramin in Treating Patients With Hormone-Refractory Prostate Cancer
Randomized phase III trial to compare the effectiveness of low, intermediate, and high dose suramin in treating men with stage IV prostate cancer that is refractory to hormone therapy.
- Trial name
- NCT00002723
- Testing
- suramin
- Where
- 27 sites in United States, South Africa
- Volunteers
- 390 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer Metastatic, Castration-resistant Prostate Cancer
ModraDoc006/r vs Docetaxel IV in Metastatic Prostate Cancer
This is a multicenter phase 2b study to evaluate the efficacy and tolerability of ModraDoc006 in combination with ritonavir (denoted ModraDoc006/r) in patients with metastatic castration-resistant prostate cancer, suitable for…
- Trial name
- NCT04028388
- Testing
- Docetaxel in Parenteral Dosage Form, ModraDoc006/r
- Where
- 28 sites in United States, Czechia and 4 more
- Volunteers
- 135 people
- Sponsor
- Modra Pharmaceuticals
Colorectal Cancer, Triple Negative Breast Cancer
Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells for Relapsed or Refractory Solid Tumour
This clinical trial is an open-label, single-centre, dose escalation, phase I study designed to investigate the safety and tolerability of Haploidentical / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted Gamma Delta…
- Conditions
- Colorectal Cancer, Triple Negative Breast Cancer, Sarcoma, Nasopharyngeal Carcinoma
- Trial name
- NCT04107142
- Testing
- Adoptive Cell Transfer of NKG2DL-targetting Chimeric Antigen Receptor-grafted Gamma Delta T cell
- Where
- Malaysia
- Volunteers
- 10 people
- Sponsor
- CytoMed Therapeutics Pte Ltd
Very High Risk Prostate Carcinoma
Neoadjuvant Lu-PSMA Radioligand Therapy and Ipilimumab in Men With Very High-risk Prostate Cancer
A randomized, open-label Phase I/II study of neoadjuvant treatment with [177Lu]Lu-PSMA-617 radioligandtherapy (LuPSMA) with or without Ipilimumab in participants with very high-risk prostate cancer who are candidates for Radical…
- Trial name
- NEPI (NCT06388369)
- Testing
- [177Lu]Lu-PSMA-617, Ipilimumab
- Where
- Germany
- Volunteers
- 1 people
- Sponsor
- University Hospital, Essen
Prostate Cancer
High-Intensity Focused Ultrasound Therapy in Treating Patients With Localized Prostate Cancer
RATIONALE: High-intensity focused ultrasound energy may be able to kill tumor cells by heating them without affecting normal tissue.
- Trial name
- NCT00561262
- Testing
- questionnaire administration, high-intensity focused ultrasound ablation, quality-of-life assessment
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- University College London Hospitals
Breast Cancer, Cognitive/Functional Effects
Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
RATIONALE: Stereotactic radiation therapy can send x-rays directly to the tumor and cause less damage to normal tissue. Radiation therapy uses high-energy x-rays to kill tumor cells.
- Conditions
- Breast Cancer, Cognitive/Functional Effects, Lung Cancer, Metastatic Cancer
- Trial name
- NCT00377156
- Testing
- radiation therapy, stereotactic radiosurgery
- Where
- 64 sites in United States, Canada
- Volunteers
- 213 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Prostatic Neoplasms
Pre-operative PET-MR of High Risk Prostate Cancer Patients for Assessment of Cancer Aggressiveness and Lymph Node Status
Prostate cancer is the most frequent cancer in Norwegian men. For optimal treatment, accurate staging of the disease at the time point of diagnosis is important.
- Trial name
- NCT02076503
- Testing
- PET-MR 18f-FACBC, histology (gold standard)
- Where
- Norway
- Volunteers
- 28 people
- Sponsor
- St. Olavs Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.